Ohki Healthcare Holdings Co.,Ltd. logo

Ohki Healthcare Holdings Co.,Ltd.

3417.T

JPXHealthcareMedical - Pharmaceuticals

Latest quote

¥1,055

¥0.00 · 0.00%

Aug 24, 11:15 AM JST

3417.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Ohki Healthcare Holdings Co.,Ltd., a venerable Japanese enterprise founded in Tokyo in 1658, operates with a broad and diversified portfolio across numerous sectors. The company primarily engages in the import, export, distribution, and sale of an extensive range of products. Its vast offerings encompass pharmaceuticals, over-the-counter drugs, medical devices, veterinary medicines, health foods, and cosmetics, alongside a wide array of daily necessities. The company also handles specialized items such as poisons and deleterious substances, reagents, measuring instruments, optical instruments, electrical products, and communication equipment. Additionally, Ohki Healthcare Holdings supplies a comprehensive selection of consumer goods, including dairy products, pet supplies, textiles, sanitary items, beauty and health equipment, sports and leisure gear, nursing care products, toys, stationery, household goods, groceries, food additives, alcoholic beverages, grains, salt, and tobacco. Its reach extends to agricultural and industrial markets, providing chemicals, fertilizers, pesticides, gardening essentials, and other agricultural supplies. Beyond its significant trading operations, the company is actively involved in manufacturing various products, including pharmaceuticals, quasi-drugs, cosmetics, health foods, killing agents, medical and sanitary items, medical skin care products, soft drinks, environmental conservation products, and diverse general merchandise. Furthermore, Ohki Healthcare Holdings offers a suite of services such as warehousing, the development and management of information processing systems, distribution system equipment, and software development. The company also manages retail pharmacies and drug stores, provides medical prescription dispensing services, operates in the nursing care sector, and facilitates license application agency services.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
JP
CEO
Hideo Matsui
Listed since
Jan 4, 2000
Employees
685

Market position

Day range

Current ¥1,055

52-week range

Current ¥1,055

Open
¥1,045
Previous close
¥1,055
Volume
15.5K
1.4× average
Average volume
11.1K
Average daily volume
Market cap
14.39B JPY
Beta
0.45
Market reference 1
50-day average
¥1,106.92
-4.69% below average
200-day average
¥1,290.86
-18.27% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
31.57B JPY
P/E (TTM)
19.22×
P/B (TTM)
0.43×
P/S (TTM)
0.04×
EV / EBITDA
26.98×
Earnings yield
7.37%
Free cash flow yield
-15.07%
Dividend yield
2.84%

Profitability & efficiency

Gross margin
4.73%
Operating margin
-0.03%
Net margin
0.21%
Return on equity
3.92%
Return on assets
0.90%
Return on invested capital
0.77%

Financial health

Debt / equity
0.63×
Current ratio
1.14×
Altman Z-score
2.73
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends6%4%2%-0%Gross margin, FY2021: 4.83%Gross margin, FY2022: 5.12%Gross margin, FY2023: 5.05%Gross margin, FY2024: 5.21%Gross margin, FY2025: 4.78%Operating margin, FY2021: 0.22%Operating margin, FY2022: 0.68%Operating margin, FY2023: 0.61%Operating margin, FY2024: 0.79%Operating margin, FY2025: 0.20%Net margin, FY2021: 0.35%Net margin, FY2022: 0.72%Net margin, FY2023: 0.66%Net margin, FY2024: 0.76%Net margin, FY2025: 0.37%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 4.83%. Gross margin FY2022 5.12%. Gross margin FY2023 5.05%. Gross margin FY2024 5.21%. Gross margin FY2025 4.78%. Operating margin FY2021 0.22%. Operating margin FY2022 0.68%. Operating margin FY2023 0.61%. Operating margin FY2024 0.79%. Operating margin FY2025 0.20%. Net margin FY2021 0.35%. Net margin FY2022 0.72%. Net margin FY2023 0.66%. Net margin FY2024 0.76%. Net margin FY2025 0.37%.

Income trends

Revenue

360.36B JPY+3.12%

Operating income

720M JPY-74.00%

Net income

1.34B JPY-49.26%
Income trends across reported periods396.33B JPY252.43B JPY108.53B JPY−35.38B JPYRevenue, FY2021: 278.16B JPYRevenue, FY2022: 304.45B JPYRevenue, FY2023: 334.66B JPYRevenue, FY2024: 349.45B JPYRevenue, FY2025: 360.36B JPYOperating income, FY2021: 600M JPYOperating income, FY2022: 2.06B JPYOperating income, FY2023: 2.04B JPYOperating income, FY2024: 2.77B JPYOperating income, FY2025: 720M JPYNet income, FY2021: 971M JPYNet income, FY2022: 2.18B JPYNet income, FY2023: 2.21B JPYNet income, FY2024: 2.64B JPYNet income, FY2025: 1.34B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 278.16B JPY. Revenue FY2022 304.45B JPY. Revenue FY2023 334.66B JPY. Revenue FY2024 349.45B JPY. Revenue FY2025 360.36B JPY. Operating income FY2021 600M JPY. Operating income FY2022 2.06B JPY. Operating income FY2023 2.04B JPY. Operating income FY2024 2.77B JPY. Operating income FY2025 720M JPY. Net income FY2021 971M JPY. Net income FY2022 2.18B JPY. Net income FY2023 2.21B JPY. Net income FY2024 2.64B JPY. Net income FY2025 1.34B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue360.36B JPY349.45B JPY334.66B JPY304.45B JPY278.16B JPY
Cost of goods sold343.12B JPY331.26B JPY317.77B JPY288.87B JPY264.74B JPY
Gross profit17.24B JPY18.19B JPY16.89B JPY15.58B JPY13.42B JPY
Research and development19M JPY24M JPY24M JPY42M JPY
Selling, general, and administrative16.52B JPY15.4B JPY14.82B JPY13.49B JPY12.75B JPY
Operating expenses16.52B JPY15.42B JPY14.85B JPY13.52B JPY12.82B JPY
Interest income27M JPY27M JPY31M JPY25M JPY22M JPY
Interest expense145M JPY71M JPY35M JPY33M JPY36M JPY
Depreciation and amortization450M JPY387M JPY377M JPY375M JPY381M JPY
Operating income720M JPY2.77B JPY2.04B JPY2.06B JPY600M JPY
Net income1.34B JPY2.64B JPY2.21B JPY2.18B JPY971M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.41

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates73.8342.8211.81-19.2Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 11, 2024: actual 42.96, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 6, 2025: actual 53.64, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 16, 2025: actual 67.41, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual 43.62, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 11, 2025: actual 42.95, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 5, 2026: actual 24.44, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual -12.78, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 0.41, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates96.91B91.96B87.01B82.07BQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 11, 2024: actual 87.96B JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 6, 2025: actual 88.63B JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 16, 2025: actual 85.79B JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual 90.52B JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 11, 2025: actual 92.23B JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 5, 2026: actual 90.86B JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 15, 2026: actual 86.75B JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 93.18B JPY, estimate —, surprise —, Comparison unavailable.

3417.T peers

ETFs holding 3417.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 3417.T

research.disclaimer